Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine adjunctive therapy for cognitive deficits and negative symptoms in schizophrenia
IRCT20200918048751N1Phase 3Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in schizophrenia comparing Memantine + routine treatment with Placebo + routine treatment (2 arms). Primary endpoints: Cognitive assessment, Quality of life and 1 more. Started Nov 2020; status: completed.
02
Drugs
memantine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20200918048751N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200918048751N1.